Marker Therapeutics, Inc. · NASDAQ:MRKR
Marker Therapeutics — Investor Presentation (September 2019)
19 slides from Marker Therapeutics's investor presentation, Sep 24, 2019
Slide 1: Marker Therapeutics: In Cell Therapy
IN CELL THERAPY fal « < = x © i. a < Ww all ina {e) fe) << = <x
Slide 2: Forward Looking Statement
Ee FORWARD LOOKING STATEMENT Certain statements contained herein are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, that involve risks and uncertainties. All statements, other
Slide 3: Investment Highlights
[SSS ee INVESTMENT HIGHLIGHTS TRANSFORMATIONAL T CELL THERAPIES Unique and highly differentiated approach that addresses the major challenges faced by CAR and TCR approaches. MULTI-ANTIGEN APPROACH DRIVES ENHANCED Durable responses with clear evidence of epitope EFFICACY Spreading targeting multiple
Slide 4: CAR T Cell Therapy
CAR T Cell Therapy Heterogeneous Tumor Mono-Specific T Cells Marker T Cells Heterogeneous Tumor ge MultiTAA T Cells Single Targeted Antigen Limited Target Recognition Multiple Targeted Antigen Multi-Target Approach Residual Tumor Lymphodepletion Prevents Endogenous immunity Epitope Spreading Jee Bib
Slide 5: MultiTAA T Cell Manufacturing Process
MULTITAA T CELL MANUFACTURING PROCESS tegen Aucogous ee 6 Oe en seytokdnes
Slide 6: TCR Profile - WT1 Reactive Cells
TCR PROFILE - WTI REACTIVE CELLS Circulating T Cells Gamma Capture Dominant Clonotypes 6 ; we uU vered “Unique” TCR 2 Undiscovered “Unique” TCR 1 240 5% 160 28% & ee a ew ee Undiscovered “Unique” TCR 3 s ;
Slide 7: Lymphoma Phase I Trial (TACTAL)
6 LYMPHOMA PHASE I TRIAL (TACTAL) Group A: Active disease (15 patients) • 7 complete responses (CR) • Durable for 4 months -- >5 years • No patient achieving a CR has subsequently relapsed • 8 stable disease (SD) • Durable for 4 -- >12 months) • 2 patients subsequently achieved CR with confounding f
Slide 8: Response in Lymphoma Trial of Patient
RESPONSE IN LYMPHOMA TRIAL OF PATIENT 5 Data demonstrates clinical benefit as post-infusion T cells exhibit antigen spreading Pre-Infusion SFC/2x10° Post-Infusion ‘SUVmax: Decreases 5.7 to 18. ES] SFC/2x10° Targeted Antigens Non-Targeted Antigens
Slide 9: Response in Lymphoma Trial of Patient
RESPONSE IN LYMPHOMA TRIAL OF PATIENT 6 Marker T cell expansion changes over time to match antigen expression on tumor Pre-infusion Post-infusion month 3 Post-infusion month 9 Non-Targeted Antigens SFC/2x10
Slide 10: AML & MDS Phase I Trial (ADSPAM)
9 AML & MDS PHASE I TRIAL (ADSPAM) Group B: Active Disease (All AML) (6 patients ⴕ ) • 1 CR: Duration 13 months • Survived 2.5 years; died of heart attack • 1 partial response (PR): Duration 4 months • Significant reduction in circulating tumor blasts • Tumor reduction from 50% to 15% and 70% to 40%
Slide 11: Clinical Course of Patient I
CLINICAL COURSE OF PATIENT I Tumor | | @ T Cells | Decitabine Elevated Liver Enzymes MultiTAA T Cells MultiTAA T Cell5 Sib. | alloHSCT Bon Bony Relapse Relapse | damm Mol0 Mott Post-oectaore —— Gtonth 570 female with AML post multiple courses of chemoRx and allo-HSCT. First Rx with MultiTAA T cells
Slide 12: Outcomes of AML/MDS Patients Post Allo-HSCT
Ee OUTCOMES OF AML/MDS PATIENTS POST ALLO-HSCT 46% Dead - 54% TRM: 25%, AML Relapse 75% 0% 50% 100% Outcome at 5 years Overall survival after relapse: 4.5 months
Slide 13: Post-Transplant AML
Ee POST-TRANSPLANT AML * Once an AML patient progresses to transplant, treatment options are very limited * Other AML therapies, such as FLT3/IDH inhibitors, are currently approved for pre-transplant use * CAR-T candidates, such as CD123 and CD33, target antigens which are prevalent on hematopoietic
Slide 14: First Line Therapy: ACCORD-11 FOLFIRINOX
FIRST LINE THERAPY ACCORD-I1: FOLFIRINOX GENERATES LONGEST OVERALL SURVIVAL BUT IS HIGHLY TOXIC © All patients with metastatic pancreatic cancer ¢ FOLFIRINOX vs. gemcitabine A. Overall Survival * FOLFIRINOX option for first line = * Median OS 11.1 months (vs. 6.8m) 6 and ORR is 31.6% (vs. 9.4%) *® M
Slide 15: First Line Therapy: MPACT Gem-Abraxane
FIRST LINE THERAPY MPACT: GEM-ABRAXANE GENERATES SHORTER OVERALL SURVIVAL BUT IS BETTER TOLERATED ¢ All patients with metastatic pancreatic cancer *¢ Gemcitabine/nab-paclitaxel vs. gemcitabine Gemcitabine/nab-paclitaxel option for first line * Median OS 8.5 months ” events/n _"“casm ed. Percentile (
Slide 16: Pancreatic Phase I/II Trial (TACTOPS Arm A)
15 PANCREATIC PHASE I/II TRIAL (TACTOPS ARM A) • Tumor biopsies showed significant T cell infiltration within the tumor • Significant T cell expansion and epitope spreading was observed in patients responding to therapy • Limited or no significant T cell expansion and epitope spreading was seen amon
Slide 17: Pancreatic Phase I/II Trial (TACTOPS) Arm A Highlights
FIRST LINE THERAPY PANCREATIC PHASE I/II TRIAL (TACTOPS) ARM A HIGHLIGHTS e 10 patients: 9 evaluable, 1 too early e 3 confirmed objective responses (OR), out of 9 evaluable patients: 1 complete response (CR) and 2 partial responses (PR) after receiving MultiTAA cells e Astable disease (SD): Notably,
Slide 18: Phase 2 Study Design for AML
17 Primary objectives are to evaluate: Relapse - free survival (RFS) (Group 1) The best overall response rate (BOR), duration of response (DOR) (Group 2) Additional objectives include: • The safety of multiple tumor associate antigen ( multiTAA ) - specific T cell therapy • OS • Graft - versus -
Slide 19: A Leading Oncology Pipeline
A LEADING ONCOLOGY PIPELINE === Oi = Mutt
Marker Therapeutics — Investor Presentation (September 2019) on 6ix